Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 13/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 13/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 12/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 12/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 12/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 9/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRE | P78334 | 1/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29548743 | 0.84 | MAPK1 (0.61) | MAPK1GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL12284552 | 0.82 | GABRG2 (0.44) | MAPK1GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL14688318 | 0.82 | MAPK1 (0.42) | MAPK1GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL163583 | 0.81 | MAPK1 (0.67) | MAPK1LMNAHCAR2DAONPC1 | |
| SCHEMBL2213943 | 0.81 | HCAR2 (0.56) | MAPK1GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL1431079 | 0.77 | HCAR2 (0.41) | MAPK1GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL14688254 | 0.77 | HPGD (0.46) | MAPK1GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL166665 | 0.76 | MAPK1 (0.43) | MAPK1ALDH1A1LMNAHCAR2DAO | |
| SCHEMBL163302 | 0.76 | KMT2A (0.54) | MAPK1ALDH1A1POLBKMT2AL3MBTL1 | |
| SCHEMBL22372059 | 0.74 | GABRG2 (0.41) | MAPK1GABRG2GABRB3GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2611437-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2611437-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029994-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, SOD3 | MAPK1 2988/4885GABRG2 3566/4885GABRB3 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.